Shilpa Medicare Limited (SHILPAMED.BO)
INR 643.55
(5.66%)
INR 643.55
(5.66%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 12.93 Billion INR | 14.65% |
| 2022 | 11.28 Billion INR | 5.98% |
| 2021 | 10.64 Billion INR | -8.63% |
| 2020 | 11.64 Billion INR | 74.45% |
| 2019 | 6.67 Billion INR | 58.97% |
| 2018 | 4.2 Billion INR | 0.18% |
| 2017 | 4.19 Billion INR | -14.1% |
| 2016 | 4.88 Billion INR | 55.61% |
| 2015 | 3.13 Billion INR | 16.66% |
| 2014 | 2.68 Billion INR | -0.91% |
| 2013 | 2.71 Billion INR | 22.09% |
| 2012 | 2.22 Billion INR | 45.98% |
| 2011 | 1.52 Billion INR | 35.88% |
| 2010 | 1.12 Billion INR | -23.54% |
| 2009 | 1.46 Billion INR | -9.6% |
| 2008 | 1.62 Billion INR | 30.23% |
| 2007 | 1.24 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 12.29 Billion INR | 0.0% |
| 2023 FY | 12.93 Billion INR | 14.65% |
| 2023 Q4 | 12.93 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q2 | 11.94 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q4 | 11.28 Billion INR | 0.0% |
| 2022 FY | 11.28 Billion INR | 5.98% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q2 | 12.11 Billion INR | 0.0% |
| 2021 Q4 | 10.64 Billion INR | 0.0% |
| 2021 FY | 10.64 Billion INR | -8.63% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 FY | 11.64 Billion INR | 74.45% |
| 2020 Q4 | 11.64 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 10.34 Billion INR | 0.0% |
| 2019 Q2 | 5.44 Billion INR | 0.0% |
| 2019 FY | 6.67 Billion INR | 58.97% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q4 | 6.67 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 4.2 Billion INR | 0.18% |
| 2018 Q4 | 4.2 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 3.55 Billion INR | 0.0% |
| 2017 FY | 4.19 Billion INR | -14.1% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q2 | 4.95 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q4 | 4.19 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 FY | 4.88 Billion INR | 55.61% |
| 2016 Q4 | 4.88 Billion INR | 0.0% |
| 2016 Q2 | 3.65 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 3.13 Billion INR | 16.66% |
| 2015 Q4 | 3.13 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 4.06 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 3.21 Billion INR | 0.0% |
| 2014 Q4 | 2.68 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 2.68 Billion INR | -0.91% |
| 2013 Q2 | 2.49 Billion INR | 0.0% |
| 2013 FY | 2.71 Billion INR | 22.09% |
| 2013 Q4 | 2.71 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2012 Q2 | 1.93 Billion INR | 0.0% |
| 2012 FY | 2.22 Billion INR | 45.98% |
| 2012 Q4 | 2.22 Billion INR | 0.0% |
| 2011 FY | 1.52 Billion INR | 35.88% |
| 2011 Q4 | 1.52 Billion INR | 0.0% |
| 2010 FY | 1.12 Billion INR | -23.54% |
| 2009 FY | 1.46 Billion INR | -9.6% |
| 2008 FY | 1.62 Billion INR | 30.23% |
| 2007 FY | 1.24 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 20.532% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 91.503% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -149.618% |
| Granules India Limited | 22.95 Billion INR | 43.66% |
| Indoco Remedies Limited | 10.34 Billion INR | -25.044% |
| Achyut Healthcare Limited | 2.01 Million INR | -642347.938% |
| Ajanta Pharma Limited | 10.71 Billion INR | -20.748% |
| Alkem Laboratories Limited | 48.6 Billion INR | 73.393% |
| Alpa Laboratories Limited | 307.12 Million INR | -4110.86% |
| Brooks Laboratories Limited | 248.6 Million INR | -5102.102% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -253.239% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -165.681% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -513.248% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 87.91% |
| Eris Lifesciences Limited | 38.26 Billion INR | 66.206% |
| FDC Limited | 3.7 Billion INR | -248.659% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 80.138% |
| Gufic Biosciences Limited | 5.59 Billion INR | -130.945% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -464.87% |
| Ipca Laboratories Limited | 33.74 Billion INR | 61.673% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -4257.891% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -334.864% |
| Lasa Supergenerics Limited | 541.92 Million INR | -2286.396% |
| Laurus Labs Limited | 42.71 Billion INR | 69.724% |
| Lupin Limited | 96.23 Billion INR | 86.562% |
| Mankind Pharma Limited | 23.87 Billion INR | 45.832% |
| Medicamen Biotech Limited | 940.36 Million INR | -1275.258% |
| Medico Remedies Limited | 438.24 Million INR | -2850.976% |
| Megasoft Limited | 1.85 Billion INR | -597.867% |
| NATCO Pharma Limited | 10.53 Billion INR | -22.792% |
| Piramal Pharma Limited | 74 Billion INR | 82.525% |
| RPG Life Sciences Limited | 1.38 Billion INR | -837.0% |
| Sigachi Industries Limited | 2.53 Billion INR | -410.91% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 92.955% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -535.743% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -1009.883% |
| Unichem Laboratories Limited | 8.06 Billion INR | -60.269% |
| Wanbury Limited | 3.15 Billion INR | -309.837% |
| Windlas Biotech Limited | 1.76 Billion INR | -633.674% |
| ZIM Laboratories Limited | 2.08 Billion INR | -521.526% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 81.986% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -232.207% |
| Divi's Laboratories Limited | 18.99 Billion INR | 31.898% |
| Hester Biosciences Limited | 3.59 Billion INR | -259.763% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -404.938% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -1549.921% |
| Bal Pharma Limited | 2.51 Billion INR | -414.976% |
| Strides Pharma Science Limited | 37.68 Billion INR | 65.679% |
| Venus Remedies Limited | 1.39 Billion INR | -828.524% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -56.744% |
| Nectar Lifesciences Limited | 11.21 Billion INR | -15.282% |
| Aarti Drugs Limited | 11.5 Billion INR | -12.417% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -104.34% |
| Suven Life Sciences Limited | 148.62 Million INR | -8601.648% |
| Ind-Swift Limited | 13.45 Billion INR | 3.869% |
| Valiant Laboratories Limited | 1.05 Billion INR | -1122.052% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -20.774% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | 8.564% |
| Themis Medicare Limited | 1.88 Billion INR | -585.16% |
| Hikal Limited | 12.99 Billion INR | 0.48% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 84.238% |
| Sequent Scientific Limited | 8.27 Billion INR | -56.298% |
| Novartis India Limited | 1.8 Billion INR | -618.032% |
| Wockhardt Limited | 39.87 Billion INR | 67.563% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 78.894% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -4378.02% |
| Neuland Laboratories Limited | 5.49 Billion INR | -135.197% |
| Morepen Laboratories Limited | 4.45 Billion INR | -189.98% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -1908.514% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -554.375% |